Please login to the form below

Not currently logged in
Email:
Password:

New finance head for Xenon

Ian Mortimer joins from Tekmira

Xenon Pharmaceuticals has appointed Ian Mortimer as chief financial officer.

Mortimer will join Xenon on November 1, 2013. He has more than 15 years' experience in the biotechnology sector.

Currently with Tekmira Pharmaceuticals Corporation, as executive VP and chief financial officer, Mortimer is responsible for all aspects of the company's finance and capital markets activities and led Tekmira's listing on Nasdaq in 2010.

Prior to joining Tekmira, Mortimer was chief financial officer at Inex Pharmaceuticals Corporation. He has an MBA from Queen's University, a BSc in microbiology from the University of British Columbia and is a Certified Management Accountant.

"We are delighted to welcome Ian to the team. He brings a combination of strong financial and operations experience that is highly relevant to Xenon," said Dr Simon Pimstone, Xenon's president and CEO.

"Given our pipeline of approved, development stage and discovery stage products and programmes, together with our strong balance sheet and our suite of major pharmaceutical partnerships, this is a good time for Xenon to be adding an experienced CFO like Ian to the company," Pimstone added.

13th September 2013

From: Sales

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics